Author: OurCrowd

[SignalRank in SignalRank] Asset managers are embracing alternatives – are VCs ready?

Sep 20, 2024 |

It seems like almost every day at the moment that an asset manager is announcing a new partnership to make alternatives go mainstream. BlackRock’s acquisition of Preqin in the summer fired the starting gun on this rush to alternatives, by signaling an intention to index private markets. Last week saw Apollo & State Street launch a “private credit” ETF (well, up to 15% of the portfolio can be private). This week saw BlackRock announce a partnership with Partners Group for an all-in-one private markets product. Read...

Read More

[AlphaTau in GlobeNewswire] Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024 |

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using the Alpha DaRT. Read more...

Read More